NO20082730L - Morfolinopyrimidinderivater og deres anvendelse i terapi - Google Patents
Morfolinopyrimidinderivater og deres anvendelse i terapiInfo
- Publication number
- NO20082730L NO20082730L NO20082730A NO20082730A NO20082730L NO 20082730 L NO20082730 L NO 20082730L NO 20082730 A NO20082730 A NO 20082730A NO 20082730 A NO20082730 A NO 20082730A NO 20082730 L NO20082730 L NO 20082730L
- Authority
- NO
- Norway
- Prior art keywords
- therapy
- morpholinopyrimidine
- derivatives
- morpholinopyrimidine derivatives
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forbindelse med formel (I): (I) eller et salt, ester eller promedikament derav, fremgangsmåter for fremstilling av dem, farmasøytiske preparater inneholdende dem og anvendelse av dem i terapi, for eksempel ved behandling av proliferativ sykdom, så som kreft, og spesielt ved sykdom mediert av en mTOR-kinase og/eller ett eller flere PI3K-enzymer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0600483A GB0600483D0 (en) | 2006-01-11 | 2006-01-11 | Novel compounds |
GB0616747A GB0616747D0 (en) | 2006-08-24 | 2006-08-24 | Novel compounds |
PCT/GB2007/000037 WO2007080382A1 (en) | 2006-01-11 | 2007-01-08 | Morpholino pyrimidine derivatives and their use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082730L true NO20082730L (no) | 2008-10-07 |
Family
ID=37946256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082730A NO20082730L (no) | 2006-01-11 | 2008-06-19 | Morfolinopyrimidinderivater og deres anvendelse i terapi |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110034454A1 (no) |
EP (1) | EP1979325A1 (no) |
JP (1) | JP2009523161A (no) |
KR (1) | KR20080083188A (no) |
AU (1) | AU2007204208A1 (no) |
BR (1) | BRPI0706395A2 (no) |
CA (1) | CA2635997A1 (no) |
IL (1) | IL192281A0 (no) |
NO (1) | NO20082730L (no) |
WO (1) | WO2007080382A1 (no) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
CA2664310A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
AU2008213808B2 (en) * | 2007-02-06 | 2011-11-10 | Novartis Ag | PI 3-kinase inhibitors and methods of their use |
US20100256143A1 (en) * | 2007-04-12 | 2010-10-07 | Stewart James Baker | Pharmaceutical compounds |
KR20100042643A (ko) * | 2007-07-09 | 2010-04-26 | 아스트라제네카 아베 | 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체 |
CN101809002B (zh) * | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
WO2009093981A1 (en) * | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
EP2283001A2 (en) * | 2008-05-13 | 2011-02-16 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
EP2326629B1 (en) | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
MX2011001196A (es) | 2008-07-31 | 2011-05-30 | Genentech Inc | Compuestos de pirimidina, composiciones y metodos de uso. |
WO2010030727A1 (en) * | 2008-09-10 | 2010-03-18 | Wyeth Llc | 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US20110166135A1 (en) * | 2008-09-10 | 2011-07-07 | Hiroshi Morimoto | Aromatic nitrogen-containing 6-membered ring compounds and their use |
RU2011116111A (ru) | 2008-09-25 | 2012-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх (De) | Сульфонилсодержащие соединения, которые селективно модулируют рецептор св2 |
KR101624000B1 (ko) | 2008-10-01 | 2016-05-24 | 노파르티스 아게 | 헷지호그 경로-관련 장애의 치료를 위한 스무슨드 길항작용 |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
CA2777128A1 (en) | 2009-10-30 | 2011-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
RU2607635C2 (ru) | 2009-11-12 | 2017-01-10 | Ф.Хоффманн-Ля Рош Аг | N-9-замещенные пуриновые соединения, композиции и способы применения |
WO2011058025A1 (en) | 2009-11-12 | 2011-05-19 | F. Hoffmann-La Roche Ag | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |
WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
UY33198A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
US9555033B2 (en) | 2010-02-03 | 2017-01-31 | Signal Pharmaceuticals, Llc | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors |
EP2542539B1 (en) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Tetrazole compounds which selectively modulate the cb2 receptor |
US8748428B2 (en) | 2010-03-30 | 2014-06-10 | Novartis Ag | Use of a PKC inhibitor |
EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
EA201201676A1 (ru) | 2010-06-25 | 2013-06-28 | Новартис Аг | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
CA2842830C (en) | 2011-07-27 | 2018-12-04 | Bayer Intellectual Property Gmbh | Substituted picolinic acids and pyrimidine-4-carboxylic acids, method for the production thereof,and use thereof as herbicides and plant growth regulators |
CN103857804A (zh) | 2011-08-03 | 2014-06-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
ME02873B (me) * | 2011-09-02 | 2018-04-20 | Purdue Pharma Lp | Pirimidini kao blokatori natrijumskog kanala |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
CA2858364C (en) * | 2011-12-05 | 2018-07-24 | Foye Opawale | Oral spray formulations and methods for administration of sildenafil |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
EP2819995B1 (en) | 2012-02-27 | 2017-02-01 | Olatec Therapeutics LLC | Process for preparing 3-methylsulfonylpropionitrile |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン |
US9637505B2 (en) | 2013-03-15 | 2017-05-02 | Dow Agrosciences Llc | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides |
BR112015026292B1 (pt) | 2013-04-17 | 2022-04-12 | Signal Pharmaceuticals, Llc | Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro |
BR112015026238A8 (pt) | 2013-04-17 | 2019-12-24 | Signal Pharm Llc | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit |
AU2014254057A1 (en) | 2013-04-17 | 2015-11-05 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
WO2014172423A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
EA029072B1 (ru) | 2013-04-17 | 2018-02-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9604939B2 (en) | 2013-05-29 | 2017-03-28 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
US10730866B2 (en) * | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
RS63190B1 (sr) | 2014-08-04 | 2022-06-30 | Nuevolution As | Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti |
TWI685302B (zh) | 2014-09-15 | 2020-02-21 | 美商陶氏農業科學公司 | 包含吡啶羧酸除草劑之安全的除草組成物 |
TWI689251B (zh) | 2014-09-15 | 2020-04-01 | 美商陶氏農業科學公司 | 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制 |
WO2016044276A1 (en) | 2014-09-15 | 2016-03-24 | Dow Agrosciences Llc | Synergistic weed control from applications of pyridine carboxylic acid herbicides and photosystem ii inhibitors |
TWI689252B (zh) | 2014-09-15 | 2020-04-01 | 美商陶氏農業科學公司 | 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶(als)抑制劑的協同性雜草控制 |
AR101858A1 (es) | 2014-09-15 | 2017-01-18 | Dow Agrosciences Llc | Composiciones herbicidas protegidas que comprenden un herbicida de ácido piridincarboxílico |
IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
EP3360872A1 (de) | 2017-02-13 | 2018-08-15 | Bayer CropScience Aktiengesellschaft | Unsubstituierte benzyl-4-aminopicolinsäureester und pyrimidin-4-carbonsäureester, verfahren zu deren herstellung sowie deren verwendung als herbizide und pflanzenwachstumsregulatoren |
CN110267951A (zh) | 2017-02-13 | 2019-09-20 | 拜耳作物科学股份公司 | 取代的苄基-4-氨基吡啶甲酸酯和嘧啶-4-甲酸酯、其制备方法以及其作为除草剂和植物生长调节剂的用途 |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10421765B2 (en) | 2017-05-26 | 2019-09-24 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase |
EA202090103A1 (ru) | 2017-06-22 | 2020-04-24 | Селджин Корпорейшн | Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b |
PT3651768T (pt) | 2017-07-13 | 2024-03-20 | Univ Texas | Inibidores heterocíclicos da atr cinase |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
CN111655688B (zh) * | 2017-09-08 | 2023-09-29 | 蓝谷制药有限责任公司 | 经取代的吡咯并吡啶类化合物作为atr抑制剂 |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
MD3755703T2 (ro) | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
EP3765008B1 (en) | 2018-03-16 | 2023-06-07 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
EP3575287A1 (en) * | 2018-05-31 | 2019-12-04 | Universiteit Leiden | Inhibitors of n-acylphosphatidylethanolamine phospholipase d (nape-pld) |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
CN109942562B (zh) * | 2019-02-27 | 2022-02-08 | 江西科技师范大学 | 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用 |
GB201908536D0 (en) * | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
CA3147918A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JP3649395B2 (ja) * | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
ATE340784T1 (de) * | 2000-11-10 | 2006-10-15 | Hoffmann La Roche | Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden |
EP2316831B1 (en) * | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
GB0415367D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
TW200628159A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
WO2006124662A1 (en) * | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
DE102005024494A1 (de) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
KR20080052630A (ko) * | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Raf 억제제 화합물 및 그의 사용 방법 |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
-
2007
- 2007-01-08 JP JP2008549922A patent/JP2009523161A/ja active Pending
- 2007-01-08 CA CA002635997A patent/CA2635997A1/en not_active Abandoned
- 2007-01-08 BR BRPI0706395-4A patent/BRPI0706395A2/pt not_active IP Right Cessation
- 2007-01-08 EP EP07700340A patent/EP1979325A1/en not_active Withdrawn
- 2007-01-08 US US12/160,752 patent/US20110034454A1/en not_active Abandoned
- 2007-01-08 AU AU2007204208A patent/AU2007204208A1/en not_active Abandoned
- 2007-01-08 WO PCT/GB2007/000037 patent/WO2007080382A1/en active Application Filing
- 2007-01-08 KR KR1020087018260A patent/KR20080083188A/ko not_active Application Discontinuation
-
2008
- 2008-06-18 IL IL192281A patent/IL192281A0/en unknown
- 2008-06-19 NO NO20082730A patent/NO20082730L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1979325A1 (en) | 2008-10-15 |
AU2007204208A1 (en) | 2007-07-19 |
US20110034454A1 (en) | 2011-02-10 |
CA2635997A1 (en) | 2007-07-19 |
IL192281A0 (en) | 2008-12-29 |
JP2009523161A (ja) | 2009-06-18 |
BRPI0706395A2 (pt) | 2011-03-22 |
KR20080083188A (ko) | 2008-09-16 |
WO2007080382A1 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082730L (no) | Morfolinopyrimidinderivater og deres anvendelse i terapi | |
NO20090631L (no) | Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser | |
NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
NI201000002A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k. | |
WO2009007751A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
WO2009007748A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
NO20084202L (no) | 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
NO20071245L (no) | Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
NO20070655L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft | |
NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
TW200621762A (en) | Novel compounds | |
NO20061743L (no) | Kinazolinderivater | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
NO20084931L (no) | Farmasoytiske sammensetninger | |
NO20091683L (no) | Kjemiske forbindelser | |
BRPI0718803B8 (pt) | composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula | |
NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi | |
NO20070681L (no) | 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft | |
AU2009282962A8 (en) | Compounds as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |